drugset / Trial / NCT01604239

To Evaluate the Safety of 'Shinbaro Capsule'in Patients With Osteoarthritis

NCT01604239 ↗

Phase 4 Completed 761 enrolled Green Cross Corporation
NaSingle-groupOpen-labelTreatment

Summary

This study investigates if Shinbaro capsule has a lower incident of gastrointestinal events than celecoxib in subjects with osteoarthritis.

Timeline

Start
2012-05
Primary completion
2013-06
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Shinbaro Capsule Traditional medicine (herbal / TCM) 600 mg Oral

Indications